Event-Driven Stocks

IMMUNE PHARMACEUTICALS INC

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs● 1 good● 1 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY17FY16FY15FY14FY13FY12
Revenue$0$0$0$2,000$19,000$7.8M
Operating income−$12.1M−$27.3M−$15.7M−$16.4M−$20.9M−$9.2M
Net income−$17.9M−$32.7M−$17.2M−$23.6M−$21.3M−$12.6M
Total assets$28.6M$19.1M$36.2M$37.9M$31.5M$4.1M
Total liabilities$14.8M$16.6M$26.7M$20.3M$26.0M$4.1M
Equity$13.8M$2.5M$7.9M$17.5M$5.5M$14,000
EPS (diluted)——————
Shares out.10.0M36.0M24.6M13.7M112.2M81.0M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2017
Operating margin
—
Net margin
—
Return on equity
−130.0%
Return on assets
−62.5%
Return on capital (ROCE)
−62.6%
Liabilities / assets
51.9%
Debt / equity
1.08×
Book value / share
$1.37
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2017
Altman Z″ (distress)
-15.32distress
Accruals / assets
−22.1%clean
Piotroski F-Score
5/8mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
38
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 1 warning● 1 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Negative operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)